Elsiglutide
Diarrhea
Helsinn Healthcare SAprotein_peptidePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Diarrhea cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Octreotide Pamoate University of Southern California | Phase 3 | BB |
Irinotecan Roswell Park Cancer Institute | Phase 3 | BB |
Loperamide Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | BB |
Sulfasalazine Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Crofelemer Napo Pharmaceuticals, Inc. | Phase 3 | BB |
View all 25 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →